肺癌PDTX模型的研究进展

发布时间：2018-07-12 11:31

  本文选题：肺肿瘤 + PDTX模型　； 参考：《中国肺癌杂志》2017年10期

【摘要】：当前随着肿瘤分子生物学及基因组学的发展,人们已经认识到同一瘤种在不同个体间其生物学特征、分子分型以及对药物干预的反应性都存在巨大的异质性,这种个体化差异是导致肿瘤治疗过程中同病同治而不同效的重要原因,因此为了实现真正的肿瘤个体化精准治疗,肿瘤研究领域提出了一个新的概念即人源肿瘤组织异种移植模型(patient derived tumor xenograft,PDTX);该模型可以真实地反映患者肿瘤组织的生物学特性以及药物疗效,是研究个体化治疗、药物耐药以及新药研发的重要手段,已被运用包括肺癌在内多个瘤种的临床诊治过程中。本文就当前肺癌PDTX模型的研究进展进行综述。
[Abstract]:At present, with the development of tumor molecular biology and genomics, it has been recognized that the biological characteristics, molecular typing and reactivity to drug intervention of the same tumor species have great heterogeneity among different individuals. This individualized difference is an important reason for the difference in the efficacy of the same disease in the course of cancer treatment, so in order to achieve true individualized and accurate treatment of the tumor, A new concept, (patient derived tumor xenograft PDTX, has been put forward in the field of tumor research, which can reflect the biological characteristics and drug efficacy of tumor tissue in patients, and is a kind of individualized therapy. Drug resistance and the important means of new drug development have been used in the clinical diagnosis and treatment of many kinds of tumors, including lung cancer. In this paper, the research progress of PDTX model for lung cancer is reviewed.
【作者单位】： 上海长征医院肿瘤科;
【基金】：上海市青年科技扬帆计划(No.17YF1425200) 上海长征医院青年启动基金(No.2015CZQN07) 国家自然科学基金(No.81702249) 上海市卫生计生委基金(No.201540174)资助~~
【分类号】：R734.2
，

本文编号：2117013